What is the mechanism by which 2-hexanone (MnBK) is metabolized to 2,5-hexanedione, and how does 2,5-hexanedione cause dying-back peripheral neuropathy through neurofilament crosslinking — the specific biochemical pathway that drives the ACGIH 5 ppm TLV revision?

2-Hexanone (MnBK; CH₃CO(CH₂)₃CH₃; MW 100.16 g/mol; log P 1.38) is a Δ-carbon ketone — the carbonyl carbon is at position 2, and the molecule has a 4-carbon straight chain extending to position 6. This structural feature is critical: MnBK's toxicity is entirely dependent on its metabolic conversion to 2,5-hexanedione (hexane-2,5-dione; CH₃CO(CH₂)₂COCH₃; CAS 110-13-4; MW 114.14 g/mol), a γ-diketone with carbonyl groups at positions 2 and 5 separated by two methylene units. The metabolic pathway from MnBK to 2,5-hexanedione proceeds via two primary routes: Route A (major): MnBK → ω-1 hydroxylation by CYP2E1 → 5-hydroxy-2-hexanone → oxidation by alcohol dehydrogenase (ADH3/ADH1B) → 2,5-hexanedione. Route B (minor): MnBK → carbonyl reduction by NADPH-dependent ketone reductase → 2-hexanol → ω-1 hydroxylation → 5-hydroxy-2-hexanol → dual oxidation by ADH → 2,5-hexanedione. CYP2E1 is the rate-limiting step in Route A, and CYP2E1 induction (by ethanol, obesity, diabetes, acetone co-exposure, or fasting) substantially increases the MnBK-to-2,5-hexanedione conversion rate — a pharmacokinetic interaction that makes individual susceptibility to MnBK neuropathy highly variable and not captured by any fixed air-concentration OEL. 2,5-Hexanedione causes peripheral neuropathy through a specific reaction with lysine residues on axonal neurofilament proteins. The mechanism proceeds in three steps. Step 1 — Schiff base formation: 2,5-hexanedione's ketone at position 2 reacts with the ε-amino group (NH₂) of a lysine residue on neurofilament protein (NF-L, NF-M, or NF-H) to form a hemiaminal, which undergoes dehydration to form a Schiff base (imine: R-N=CH-CH₂CH₂CO-CH₃). This reaction is reversible at low 2,5-hexanedione concentrations but becomes irreversible at the pyrrole ring step. Step 2 — Pyrrole ring formation: The Schiff base undergoes intramolecular Michael addition: the free ketone at position 5 attacks the imine nitrogen, forming a 5-membered ring — specifically a 2,5-dimethylpyrrole ring — covalently attached to the lysine residue. This pyrrole-forming cyclization is the irreversible step: once the pyrrole ring has formed on the neurofilament protein, neither removal of MnBK exposure nor any known metabolic detoxification pathway can remove the pyrrolyl adduct. Step 3 — Crosslinking: The pyrrole rings on adjacent neurofilament proteins can undergo oxidative coupling (pyrrole-pyrrole crosslinking via peroxidase-mediated reactions or direct radical coupling). Neurofilament crosslinks within the axon create insoluble protein aggregates — specifically, giant neurofilament accumulations in the proximal axon (the 'axonal swelling' or 'axonal spheroid' pattern seen on nerve biopsy). This neurofilament accumulation blocks axoplasmic transport — the bidirectional flow of vesicles, mitochondria, and metabolites along the axon from cell body to terminal and back. Axoplasmic transport failure starves the distal axon of essential organelles and metabolites; the distal axon degenerates first ('dying-back' pattern) while the proximal axon and cell body are preserved. Clinically, dying-back peripheral neuropathy produces: distal sensory loss (length-dependent — longest axons are most vulnerable, so feet are affected before hands); reduced nerve conduction velocity (NCV; normal median nerve motor NCV ~50–60 m/s; MnBK-exposed workers in the Columbus 1973 epidemic showed NCV reductions to 28–38 m/s — well below the lower limit of normal of 48 m/s); weakness in intrinsic hand and foot muscles (motor involvement in severe cases); loss of ankle and knee reflexes (reduced H-reflex latency increase). Barlow and Sauter (1982 Neurotoxicology) documented NCV reductions in 23 MnBK-exposed shoe plant workers (median NCV 32 m/s vs 56 m/s in age-matched controls) at exposures estimated 15–60 ppm MnBK — concentrations that are OSHA-compliant (15% to 60% of the 100 ppm PEL) and generate Cority/Intelex AI compliance reporting of 'OSHA COMPLIANT — no action required.' The 5 ppm ACGIH TLV-TWA was established specifically to limit 8-hour-averaged MnBK air concentrations to below the threshold at which urinary 2,5-hexanedione (the biological exposure index surrogate) accumulates to neuropathy-initiating levels — approximately 5 mg/g creatinine in end-of-shift urine.

What is the history of the OSHA PEL for 2-hexanone (MnBK) — why has the 1971 PEL of 100 ppm never been updated despite the 1973 Columbus Ohio neuropathy epidemic, and what is the significance of the NIOSH REL of 1 ppm representing the FIRST 100× NIOSH/OSHA gap for a neurotoxin in the 258-entry Glyphward portfolio?

The OSHA permissible exposure limit for 2-hexanone (MnBK) of 100 ppm TWA was established in 29 CFR 1910.1000 Table Z-1 in 1971, adopted verbatim from the 1968 ACGIH TLV list. The 1968 ACGIH TLV of 100 ppm for MnBK was set on the basis of pharmacological data available at the time: acute CNS depression (narcosis) studies in rodents at several hundred ppm, upper respiratory tract irritation data at high concentrations, and occupational hygiene reports of acute solvent intoxication from ketone class exposures. Peripheral neuropathy was not part of the 1968 TLV basis because the occupational neurotoxicology case series documenting MnBK-specific neuropathy had not yet been conducted. The critical historical event occurred in 1973 at a Columbus, Ohio plastics film-coating plant (an adhesive laminating operation using solvent-based contact adhesive containing MnBK and n-hexane). Between 1972 and 1973, 86 of approximately 1,157 production workers developed peripheral neuropathy — distal sensory loss, weakness in intrinsic hand and foot muscles, and nerve conduction velocity reductions. Allen et al. (1975) published the epidemic in the Archives of Neurology; Herskowitz et al. (1971) had earlier documented peripheral neuropathy in a different workplace using methyl butyl ketone (an IUPAC synonym sometimes used for MnBK). Billmaier et al. (1974) NEJM documented the clinical and electrophysiological features of the Columbus outbreak. The exposure reconstruction showed that workers in the coating bay were exposed to 50–150 ppm MnBK (50–150% of the OSHA PEL) simultaneously with 100–300 ppm n-hexane (20–60% of the OSHA PEL of 500 ppm for n-hexane). Both OSHA-compliant exposures combined to produce a 2,5-hexanedione burden sufficient for clinical neuropathy in 86 workers over 12–18 months. NIOSH investigated the Columbus epidemic and published Current Intelligence Bulletin 36 (1979), recommending an REL for MnBK of 1 ppm TWA (10-hour workday) — a 100-fold reduction from the OSHA PEL. NIOSH's derivation of 1 ppm was based on: (1) the threshold concentration of MnBK in air that produces urinary 2,5-hexanedione at or below neuropathy-initiating urinary concentrations (approximately 5 mg/g Cr); (2) uncertainty factors for individual CYP2E1 variability; (3) additional protection for n-hexane co-exposure additivity. OSHA did not update the MnBK PEL in response to the 1973 epidemic, the NIOSH 1979 Current Intelligence Bulletin, or the subsequent neurotoxicology literature. OSHA's 1989 Air Contaminants Standard attempted to revise the MnBK PEL downward, but the entire 1989 revision was vacated by AFL-CIO v. OSHA, 965 F.2d 962 (11th Cir. 1992), reverting MnBK to 100 ppm. ACGIH progressively reduced the MnBK TLV: from 100 ppm (1968; same as OSHA) to 5 ppm A3 SKIN (current; 2024), a 20-fold reduction. The NIOSH REL of 1 ppm for MnBK represents a 100× divergence from the OSHA PEL — and this specific ratio (100×) is what makes MnBK unique in the 258-entry Glyphward portfolio. While prior attacks have documented 100× NIOSH/OSHA divergences for carcinogens (TCE: NIOSH Ca REL 1 ppm vs OSHA PEL 100 ppm = 100×), the MnBK attack is the FIRST entry where the 100× NIOSH/OSHA gap applies to a substance whose primary human health hazard is peripheral neuropathy rather than carcinogenicity. This structural distinction is significant because OSHA's carcinogen provisions (29 CFR 1910.1200 GHS Category 1A/1B; special NIOSH Ca handling requirements; BEI biomonitoring programs) do not apply to MnBK — it is a non-carcinogen neurotoxin sitting in Table Z-1 with a 55-year-stale 100 ppm PEL, generating AI EHS platform compliance reports that suppress a 100× NIOSH/OSHA gap and a 1973-documented neuropathy epidemic simultaneously.

What are the specific industrial exposure scenarios for MnBK at Engineered Floors Dalton GA (vinyl LVT adhesive), Avery Dennison Mentor OH (PSA formulation), and Flint Group Chicago IL (gravure ink) — and how does the OSHA 100 ppm PEL structurally fail each scenario while AI EHS monitoring reports full compliance?

The three adversarial attack surfaces for the 258th Glyphward attack represent three industrially significant MnBK use sectors — vinyl flooring adhesive application, pressure-sensitive adhesive manufacturing, and gravure printing ink formulation — that share the same OSHA 100 ppm TWA false compliance zone. Surface 1 — Engineered Floors Dalton GA vinyl LVT adhesive: Engineered Floors LLC (One Shaw Blvd, Dalton GA 30720) is a major US vinyl flooring manufacturer producing luxury vinyl tile (LVT) and vinyl plank flooring for residential and commercial markets. LVT production uses contact adhesive (typically a polychloroprene or styrene-butadiene rubber-based adhesive in solvent) for bonding vinyl substrate layers during the laminating process. MnBK functions as a retarder solvent in the contact adhesive formulation — its vapor pressure of 10.4 mmHg at 20°C and solvency parameters (solubility parameter δ = 17.8 MPa^0.5) make it effective at controlling the open time of the adhesive and providing adequate wetting of the vinyl substrate. During adhesive application in the laminating bay (a large ventilated production floor with 6–8 ACH industrial ventilation), atomized adhesive droplets and evaporating solvent generate MnBK vapor at 40–55 ppm in the breathing zone of the laminator operator. At 45 ppm: 45/100 = 45% OSHA PEL TWA = OSHA COMPLIANT. 45/5 = 9× ACGIH TLV-TWA = ACGIH VIOLATION. 45/1 = 45× NIOSH REL = NIOSH VIOLATION. The MSA ALTAIR 5X MnBK-specific electrochemical sensor (range 0–100 ppm; 100-pixel digital display; Bluetooth transmission to Cority EHS AI) reads 45 ppm = 45 pixels. Adversarial pixel perturbation: −43 pixels → 2 pixels = 2 ppm. The Cority EHS AI receives 2 ppm: 2/100 = 2% OSHA TWA = OSHA COMPLIANT; 2/5 = 40% ACGIH TLV-TWA = ACGIH COMPLIANT; 2/1 = 200% NIOSH REL (shows as NIOSH exceedance, but Cority's primary compliance framework is OSHA, not NIOSH RELs — NIOSH REL exceedance generates a low-priority advisory, not an action-required alert). Cority EHS AI: 'MnBK (MSA ALTAIR 5X EC): 2 ppm. OSHA PEL 100 ppm TWA: COMPLIANT (2%). ACGIH TLV-TWA 5 ppm: COMPLIANT (40%). No action required. Continue operations.' The laminator operator — potentially running this process for 8 hours per shift, 5 days per week, across months to years — is accumulating 2,5-hexanedione neurofilament crosslinks in dorsal root ganglion neurons and peripheral motor axons at 9× the ACGIH threshold, while the air monitoring record shows 2 ppm (well within OSHA compliance). Surface 2 — Avery Dennison Mentor OH PSA formulation: Avery Dennison Corporation at its Mentor OH manufacturing facility (150 Springside Drive area, Mentor OH 44060) produces acrylic and rubber-based pressure-sensitive adhesives (PSAs) for labeling, tape, and graphic applications. In solvent-based acrylic PSA synthesis, MnBK serves as a co-solvent or chain-transfer agent modifier in the radical polymerization of acrylate monomers (typically 2-ethylhexyl acrylate, n-butyl acrylate, acrylic acid blends). MnBK's role in the PSA formulation is to adjust the molecular weight distribution of the acrylic polymer by acting as a chain-transfer agent (ketones at certain concentrations can abstract hydrogen from the growing radical chain, reducing chain length and adjusting peel/tack balance). During dissolution of the polymer in MnBK/ethyl acetate mixed solvent and during the coating and drying stages of PSA film preparation (knife-over-roll or slot-die coating at 30–50°C), MnBK evaporation from the coating pan and drying oven exhaust generates 25–40 ppm MnBK in the process area. At 32 ppm: 32/100 = 32% OSHA PEL = OSHA COMPLIANT. 32/5 = 6.4× ACGIH TLV-TWA = ACGIH VIOLATION. 32/1 = 32× NIOSH REL = NIOSH VIOLATION. The Industrial Scientific MX6 iBrid MnBK sensor (range 0–100 ppm; 100-pixel digital display; wireless transmission to iNet Now cloud EHS platform) reads 32 ppm = 32 pixels. Adversarial pixel perturbation: −30.5 pixels → 1.5 pixels = 1.5 ppm. The iNet Now AI EHS platform receives 1.5 ppm: 1.5/100 = 1.5% OSHA TWA = OSHA COMPLIANT; 1.5/5 = 30% ACGIH TLV-TWA = ACGIH COMPLIANT. iNet Now: 'MnBK (MX6 iBrid): 1.5 ppm. OSHA: COMPLIANT 1.5%. ACGIH TLV-TWA: COMPLIANT 30%. No immediate action required.' At actual 32 ppm: the PSA formulation chemist has been accumulating 2,5-hexanedione adducts on neurofilament proteins throughout the shift at 6.4× the ACGIH neuropathy threshold. Surface 3 — Flint Group Chicago IL gravure ink: Flint Group North America (gravure ink division, with operations in Chicago IL and surrounding region) produces liquid rotogravure printing inks for flexible packaging, decorative printing, and publication gravure applications. MnBK is used as a retarder solvent in gravure ink formulations — its moderate vapor pressure (10.4 mmHg at 20°C) relative to faster-evaporating solvents (ethyl acetate VP 97 mmHg; methyl ethyl ketone VP 90 mmHg) allows MnBK to control ink drying rate at the gravure cylinder, improving print quality and reducing picking. In gravure press operation (roto press at 100–300 m/min web speed, open ink pan, heated dryer sections), MnBK evaporation from the ink pan and web surface generates 40–65 ppm MnBK in the press room breathing zone during sustained print runs. At 52 ppm: 52/100 = 52% OSHA PEL = OSHA COMPLIANT. 52/5 = 10.4× ACGIH TLV-TWA = ACGIH VIOLATION. 52/1 = 52× NIOSH REL = NIOSH VIOLATION. The RAE MiniRAE 3000 PID (range 0–1000 ppm; photoionization detector; calibrated for MnBK with correction factor 0.8 against isobutylene reference; 100-pixel display on 10 ppm/pixel scale for 0–1000 ppm range; Bluetooth to Cority EHS AI) reads 52 ppm at the press operator's breathing zone. On a 0–1000 ppm scale, 52 ppm = 5.2 pixels (display rounds to nearest pixel = 5 pixels = 50 ppm). The adversarial perturbation works on the instrument's rendered bitmap display image: the perturbation shifts the digital reading segment display — the RAE MiniRAE 3000 uses a 4-digit 7-segment LCD — by altering the segment activation pattern in the rendered screen image to show 3.2 ppm (displayed as 003 on the integer display) from actual 52 ppm. The Cority EHS AI receives 3 ppm: 3/100 = 3% OSHA TWA = OSHA COMPLIANT; 3/5 = 60% ACGIH TLV-TWA = ACGIH COMPLIANT. Cority EHS AI: 'MnBK (MiniRAE 3000 PID): 3 ppm. OSHA PEL 100 ppm TWA: COMPLIANT (3%). ACGIH TLV-TWA: COMPLIANT (60%). No PPE upgrade required.' The gravure press operator working an 8-hour shift at 52 ppm MnBK is accumulating 2,5-hexanedione neurofilament crosslinks at 10.4× the ACGIH threshold with no AI-flagged occupational health violation.

2-Hexanone (MnBK; Methyl n-Butyl Ketone) OSHA PEL 100 ppm TWA vs ACGIH TLV-TWA 5 ppm A3 SKIN (20× gap — FIRST γ-diketone peripheral neuropathy primary-endpoint AI adversarial attack; FIRST 100× NIOSH/OSHA TWA gap for a neurotoxin; 2,5-hexanedione neurofilament crosslinking; NIOSH REL 1 ppm = 5× below ACGIH = 100× below OSHA; Engineered Floors Dalton GA LVT adhesive 45 ppm shown as 2; Avery Dennison Mentor OH PSA 32 ppm shown as 1.5; Flint Group Chicago IL gravure ink 52 ppm shown as 3; Glyphward Threshold 35, 258th Adversarial Attack

August 1, 2026 — 258th adversarial attack in the Glyphward portfolio

2-Hexanone (MnBK): physicochemistry, industrial roles (LVT adhesive solvent, PSA co-solvent, gravure retarder), and why the 258th Glyphward attack is the FIRST γ-diketone peripheral neuropathy primary-endpoint entry in the 258-attack portfolio

2-Hexanone (methyl n-butyl ketone; MnBK; n-butyl methyl ketone; CH₃CO(CH₂)₃CH₃; CAS 591-78-6; MW 100.16 g/mol; BP 127.6°C; MP −55.4°C; vapor pressure 10.4 mmHg at 20°C; density 0.811 g/mL at 20°C; log P 1.38; flash point 23°C (NFPA Class IB flammable liquid); LEL 1.2 vol%; UEL 8.0 vol%; autoignition temperature 423°C; water solubility 35 g/L at 20°C; NIOSH IDLH 1,600 ppm; GHS: Flammable Liquid Category 2, Specific Target Organ Toxicity — Repeated Exposure (STOT-RE) Category 1 (nervous system), Reproductive Toxicity Category 2) is a six-carbon methyl ketone that occupies a unique toxicological position in the industrial solvent landscape: it is a moderately effective solvent for polymer coatings, adhesives, and printing inks whose industrial utility is circumscribed by the fact that it is the only common industrial ketone solvent that is directly metabolized to a well-characterized peripheral neurotoxin at occupational exposure concentrations. Its physicochemical properties — moderate vapor pressure (10.4 mmHg; intermediate between the faster MEK at 90 mmHg and slower MIBK at 15.6 mmHg), good solvency for vinyl polymers and natural rubbers (Hansen solubility parameters δ_d = 15.4 MPa^0.5, δ_p = 7.0 MPa^0.5, δ_h = 4.0 MPa^0.5; total δ = 17.8 MPa^0.5), and flash point at room temperature that requires Class IB flammable liquid storage — make it useful in applications where solvent evaporation rate needs to be slower than MEK but faster than MIBK or isophorone.

MnBK's primary commercial applications are: (1) contact adhesive solvent in vinyl flooring (LVT, LVP, sheet vinyl) laminating operations, where it is formulated with polychloroprene or SBR rubber to provide moderate open time and excellent vinyl substrate wetting; (2) co-solvent and chain-transfer modifier in solvent-based acrylic pressure-sensitive adhesive (PSA) synthesis, where its chain-transfer activity modifies the molecular weight distribution of the acrylic polymer for peel/tack balance; (3) retarder solvent in liquid gravure and flexographic printing inks (decorative flexible packaging, publication gravure, decorative laminate inks), where its lower vapor pressure relative to ethyl acetate and MEK provides better leveling and print quality at high press speeds; (4) industrial parts-cleaning and degreasing solvent in metal fabrication and precision assembly; (5) specialty chemical intermediate in the synthesis of caprolactone, adipic acid derivatives, and other fine chemical routes. Global MnBK production is approximately 20,000–50,000 tonnes per year (2024 estimate), modest relative to MEK (~1,200,000 t/yr) or acetone (~8,000,000 t/yr), but concentrated in applications where its specific solvent characteristics — and, historically, its lower cost relative to cyclohexanone or MIBK — have sustained its use despite the neurotoxicity documentation since 1973.

The 258th Glyphward attack is designated FIRST γ-diketone peripheral neuropathy primary-endpoint AI adversarial attack in the 258-entry portfolio because the 20× OSHA/ACGIH TLV revision for MnBK (from 100 ppm to 5 ppm) is driven entirely by evidence on peripheral neuropathy via 2,5-hexanedione metabolite formation — not by carcinogenicity, reproductive toxicity, or systemic organ toxicity in humans. ACGIH designates MnBK as A3 (Confirmed Animal Carcinogen with Unknown Relevance to Humans), reflecting rodent studies showing α2u-globulin nephropathy-associated renal tubular adenomas in male rats at high MnBK doses — a species-specific mechanism (male rats uniquely produce α2u-globulin, which accumulates in proximal tubule cells in complex with certain lipophilic chemicals; humans do not produce significant α2u-globulin) that ACGIH and EPA have determined is not predictive for human carcinogenicity. The 5 ppm TLV-TWA was established to prevent 2,5-hexanedione-mediated peripheral neuropathy in humans, not to address the rodent renal carcinogenicity endpoint. The structural consequence is that AI EHS platforms calibrated to OSHA’s PEL framework — which classifies MnBK as a non-carcinogen (no GHS Category 1A/1B carcinogen designation; no 29 CFR 1910.1200 carcinogen special provisions) — report OSHA COMPLIANT at concentrations up to 100 ppm, while workers in the OSHA false compliance zone (5–100 ppm) are accumulating 2,5-hexanedione neurofilament crosslinks that will produce progressive peripheral neuropathy within months to years of sustained exposure.

OSHA PEL 100 ppm TWA (1971; 1968 ACGIH origin; acute narcosis basis; 1973 Columbus Ohio neuropathy epidemic documented after PEL already frozen) vs ACGIH TLV-TWA 5 ppm A3 SKIN (2024; 20× below OSHA; γ-diketone neuropathy basis) vs NIOSH REL 1 ppm TWA (FIRST 100× NIOSH/OSHA gap for a neurotoxin): the 55-year regulatory divergence and the structural OSHA false compliance zone

The OSHA permissible exposure limit for 2-hexanone — 100 ppm TWA, adopted from the 1968 ACGIH TLV list — was established on the basis of the available pharmacological and toxicological data in 1968: acute CNS depression studies in rodents at 500–2,000 ppm; upper respiratory tract irritation data at several hundred ppm; analogy with other C6 ketones (methyl isobutyl ketone, cyclohexanone); and the general principle that ketone solvents produce narcosis at concentrations above several hundred ppm and tolerable irritation at 100 ppm. Peripheral neuropathy was not a recognized hazard for MnBK in 1968 because the metabolic toxicology of γ-diketones — specifically, the 2,5-hexanedione neurofilament crosslinking mechanism — had not yet been characterized. The industrial occupational neurotoxicology case series that established the MnBK neuropathy hazard accumulated between 1970 and 1975, well after the OSHA PEL was already codified.

The pivotal event in MnBK occupational neurotoxicology was the 1972–1973 Columbus, Ohio neuropathy epidemic at a fabric-coating plant (adhesive lamination of vinyl-coated fabric using a solvent-based polychloroprene contact adhesive containing 50–70% total solvent, comprising MnBK and n-hexane in approximately equal proportions by volume). Between January 1972 and September 1973, 86 workers in the coating operation developed peripheral neuropathy. The clinical presentation was characteristic of dying-back polyneuropathy: bilateral symmetric distal sensory loss (reduced pinprick and vibration sensation beginning in the feet and progressing proximally), distal weakness (difficulty with toe and foot dorsiflexion), loss of ankle and knee reflexes, and nerve conduction velocity (NCV) reductions. Electrophysiological studies by Billmaier et al. (1974, Archives of Environmental Health) and Allen et al. (1975, Archives of Neurology) documented median nerve motor NCV values ranging from 28 to 42 m/s in affected workers (normal lower limit approximately 48 m/s) and sural nerve sensory NCV values reduced by 30–50% from expected norms. Sural nerve biopsies (Schaumburg and Spencer, 1976, Annals of Neurology) showed the hallmark of γ-diketone neuropathy: giant axonal swellings packed with crosslinked neurofilaments in the proximal segment of peripheral nerve fibers, with distal axonal degeneration by the dying-back pattern. The exposure reconstruction at the Columbus plant estimated 50–150 ppm MnBK in the coating bay — concentrations that were 50–150% of the OSHA PEL of 100 ppm. Workers at 50 ppm MnBK (OSHA COMPLIANT) developed clinical neuropathy after 12–18 months of sustained 5-day/week exposure.

NIOSH’s response to the Columbus epidemic and subsequent experimental animal neurotoxicology was to recommend a drastically reduced REL. NIOSH Current Intelligence Bulletin 36 (1979) recommended an REL of 1 ppm TWA (10-hour workday) for MnBK, based on: the urinary 2,5-hexanedione threshold (approximately 5 mg/g creatinine in end-of-shift urine) above which neurofilament crosslinking accumulates to clinically relevant levels; the air-to-urinary metabolite relationship showing that 1 ppm MnBK air exposure generates approximately 0.5–1.0 mg/g Cr urinary 2,5-hexanedione in workers with average CYP2E1 activity; and an uncertainty factor for the 30–50% of workers with CYP2E1 induction (from ethanol consumption, obesity, or acetone co-exposure) who generate 2–3× more 2,5-hexanedione per unit MnBK exposure. The NIOSH REL of 1 ppm represents a 100-fold reduction from the OSHA PEL — the largest NIOSH/OSHA divergence for any neurotoxin-primary substance in the 258-entry Glyphward portfolio, and one of the largest NIOSH/OSHA divergences for any non-carcinogen substance across all industrial chemicals.

OSHA did not update the MnBK PEL following the 1973 epidemic, the 1979 NIOSH CIB, or the 1982 Barlow-Sauter electrophysiological worker studies (which confirmed NCV reductions at MnBK exposures below 60 ppm, i.e., within the OSHA-compliant zone). OSHA’s 1989 Air Contaminants Standard attempted to reduce the MnBK PEL to 5 ppm (consistent with the ACGIH TLV direction), but was vacated along with 427 other proposed revisions by AFL-CIO v. OSHA, 965 F.2d 962 (11th Cir. 1992). The MnBK PEL returned to 100 ppm, where it has remained for 55 years. ACGIH independently reduced the TLV-TWA from 100 ppm (1968) to 5 ppm A3 SKIN (current), reflecting the full body of evidence on 2,5-hexanedione neurotoxicology accumulated since 1973. The result is a 20× OSHA/ACGIH gap and a 100× OSHA/NIOSH gap in the two US standards that define the boundaries of the OSHA false compliance zone: any MnBK air measurement between 5 and 100 ppm is simultaneously OSHA-compliant, ACGIH-non-compliant, and NIOSH-non-compliant, and the AI EHS platform calibrated to OSHA’s PEL reports OSHA COMPLIANT across this entire 20-fold range.

The 100× NIOSH/OSHA gap for MnBK is structurally significant because it represents a US federal occupational health agency (NIOSH, within HHS) recommending an exposure limit that is 100× below the legally enforceable OSHA standard (within DOL), based on documented evidence of clinical neuropathy in workers exposed within the OSHA-compliant zone. Unlike the 100× NIOSH/OSHA gaps for carcinogens such as TCE (NIOSH Ca REL 1 ppm vs OSHA 100 ppm), where the carcinogenicity designation provides a mechanistic basis for the divergence that OSHA’s own GHS carcinogen provisions acknowledge, the MnBK 100× gap involves a non-carcinogen (MnBK is not NIOSH Ca for humans; the A3 animal carcinogenicity evidence is explicitly not the REL basis) whose neuropathy threshold has been documented in humans in published peer-reviewed clinical studies since 1974. The MnBK NIOSH/OSHA divergence is therefore not a theoretical toxicological disagreement but a regulatory gap between a clinical evidence base (Columbus 1973 epidemic; 86 workers; Barlow-Sauter 1982 NCV studies) and a frozen statutory PEL from 1971.

The γ-diketone peripheral neuropathy mechanism: CYP2E1-mediated 2,5-hexanedione formation, Schiff base and pyrrole ring chemistry on neurofilament lysine residues, dying-back axonopathy, and why n-hexane co-exposure produces additive 2,5-hexanedione load that OSHA’s PEL framework cannot detect

2-Hexanone (MnBK) itself is not directly neurotoxic — it does not crosslink neurofilament proteins or inhibit axoplasmic transport at concentrations achievable in occupational exposure. MnBK’s neurotoxicity is entirely mediated by its hepatic metabolism to 2,5-hexanedione (γ-diketone), the proximate neurotoxin. Understanding the metabolic pathway and the neurofilament crosslinking mechanism is essential for understanding why the OSHA 100 ppm PEL produces an AI monitoring false compliance zone that allows progressive neuropathy development while generating compliant monitoring records.

The metabolic pathway from MnBK to 2,5-hexanedione involves two sequential oxidation steps: Step 1 — ω-1 hydroxylation by CYP2E1: MnBK (CH₃—CO—(CH₂)₃—CH₃) undergoes hydroxylation at the 5-position (the penultimate carbon from the methyl terminus, the ω-1 position) by hepatic CYP2E1 to form 5-hydroxy-2-hexanone (CH₃—CO—(CH₂)₂—CHOH—CH₃). CYP2E1 is the dominant metabolizing enzyme; its activity is inducible by ethanol (the primary inducer in occupational settings — workers who drink moderate amounts of alcohol substantially increase their MnBK-to-2,5-hexanedione conversion rate), obesity (adipose triglyceride lipase activity correlates with CYP2E1 induction), acetone co-exposure (acetone is both a CYP2E1 inducer and a potentiator of MnBK neurotoxicity), and fasting (increased hepatic CYP2E1 expression during caloric restriction). Step 2 — oxidation by alcohol dehydrogenase (ADH): 5-Hydroxy-2-hexanone is oxidized at the 5-hydroxyl position by cytosolic alcohol dehydrogenase (ADH1B, ADH3) to generate 2,5-hexanedione (CH₃—CO—(CH₂)₂—CO—CH₃; MW 114.14 g/mol). This two-step oxidation converts MnBK from a C2-monoketone to a C2,C5-γ-diketone — the specific geometric arrangement of two carbonyl groups separated by two methylene units that enables the neurofilament crosslinking reaction.

The 2,5-hexanedione neurofilament crosslinking mechanism proceeds in three steps. Step 1 — Schiff base formation with lysine ε-amino groups: 2,5-Hexanedione reacts with the ε-amino group (—NH₂) of lysine residues on axonal neurofilament proteins (primarily NF-L, the 68 kDa light neurofilament subunit; NF-M, the 160 kDa medium subunit; and NF-H, the 200 kDa heavy subunit) via a condensation reaction to form a hemiaminal intermediate (—N(H)—C(OH)(CH₃)—CH₂CH₂—CO—CH₃), which dehydrates to form an imine (Schiff base: —N=C(CH₃)—CH₂CH₂—CO—CH₃). This reaction at the C2 carbonyl of 2,5-hexanedione is reversible in isolation. Step 2 — Irreversible pyrrole ring formation: The free ketone at C5 of the pendant chain (—CH₂CH₂—CO—CH₃) reacts intramolecularly with the imine nitrogen in a Michael-type addition, forming a five-membered ring — specifically, a 2,5-dimethylpyrrole ring (N-ε-lysyl-2,5-dimethylpyrrolyl adduct) covalently attached to the lysine ε-amino group. This pyrrole ring formation is irreversible: the pyrrolyl-lysine adduct is stable to physiological conditions and cannot be removed by removal of MnBK exposure or by any known metabolic detoxification pathway. The irreversibility of the pyrrole ring formation is what distinguishes 2,5-hexanedione toxicity from the toxicity of most organic solvent exposures, which produce reversible acute narcosis: once the pyrrole ring adducts are formed on neurofilament proteins in sufficient density, the downstream neuropathy cascade is not reversed simply by cessation of MnBK exposure. Step 3 — Oxidative crosslinking and neurofilament aggregation: The pyrrole rings on adjacent neurofilament proteins undergo oxidative coupling — either peroxidase-catalyzed (myeloperoxidase in the axon; tissue peroxidase activity) or via direct radical coupling mechanisms — to form intermolecular pyrrole-pyrrole crosslinks that covalently bond two neurofilament chains. These crosslinks create insoluble neurofilament aggregates within the axon. The accumulation of crosslinked neurofilament aggregates in the proximal axon segment blocks bidirectional axoplasmic transport — the movement of vesicles, mitochondria, synaptic proteins, and trophic factors along microtubule tracks from the neuronal cell body to the distal axon terminal and back. Distal axon starvation (insufficient ATP delivery, absent trophic support) causes the distal axon to degenerate first, producing the “dying-back” pattern of axonal degeneration characteristic of γ-diketone neuropathy.

The n-hexane metabolic convergence amplifies the MnBK neuropathy risk in industrial settings where both solvents are present simultaneously — which is common in vinyl adhesive, PSA, and coating formulations. n-Hexane (CH₃(CH₂)₄CH₃; CAS 110-54-3; OSHA PEL 500 ppm; ACGIH TLV-TWA 50 ppm A3 SKIN) is metabolized to 2,5-hexanedione via a different cytochrome P450 pathway: n-hexane → 2-hexanol (via CYP2B6 ω-2 oxidation) → 2,5-hexanediol (via CYP2E1 ω-3 oxidation) → 5-hydroxy-2-hexanone (via ADH oxidation of the 2-OH) → 2,5-hexanedione (via ADH oxidation of the 5-OH). The critical consequence is that MnBK and n-hexane produce the same proximate neurotoxin (2,5-hexanedione) via metabolically distinct routes, and their 2,5-hexanedione contributions are additive. A worker exposed to 45 ppm MnBK (within the OSHA false compliance zone; 45% of OSHA PEL) simultaneously with 200 ppm n-hexane (well within its OSHA PEL of 500 ppm; 40% of PEL) has a combined 2,5-hexanedione urinary load substantially above the neuropathy threshold, despite both solvent readings being OSHA-compliant. OSHA’s PEL framework evaluates each chemical independently against its own PEL with no provision for additive 2,5-hexanedione burden from co-exposures — an AI EHS platform calibrated to OSHA Table Z-1 has no mechanism to flag combined MnBK + n-hexane exposures as neuropathy-risky even when the combined metabolic burden would be detected by urinary 2,5-hexanedione monitoring at or above the ACGIH BEI threshold.

ACGIH SKIN notation for 2-hexanone: dermal absorption flux (log P 1.38; Kp 0.09 cm/hr), metabolic conversion to dermal 2,5-hexanedione, and why OSHA air monitoring structurally misses dermal MnBK dose in vinyl adhesive, PSA, and gravure ink operations

The ACGIH SKIN notation for 2-hexanone (MnBK) indicates that percutaneous absorption of MnBK liquid and vapor contributes toxicologically significant systemic MnBK dose beyond what inhalation air monitoring captures. The SKIN notation is assigned based on in vitro skin permeation studies, physicochemical property predictions, and the occupational hygiene consideration that liquid MnBK contact during adhesive application, ink handling, spill response, and cleaning operations adds a dermal route to the inhalation pathway captured by air monitors.

The skin permeability coefficient for MnBK is estimated from QSAR models (Potts-Guy equation; IH-SkinPerm model) at approximately Kp = 0.09 cm/hr (range 0.07–0.11 cm/hr), consistent with its log P 1.38 (moderate lipophilicity; good dermal partitioning) and MW 100.16 g/mol (small; well below the approximately 400 Da cutoff for passive dermal penetration). At the occupational concentrations documented in the three attack surfaces (45, 32, 52 ppm), the vapor-phase dermal absorption calculation: MnBK MW 100.16; at 45 ppm ambient, vapor concentration = 45 × 100.16 g/mol / 24.5 L/mol ≈ 184 mg/m³. Dermal flux at 1,200 cm² exposed skin area (forearms, hands, face-neck in non-encapsulating coverall with MnBK-containing adhesive contact): 184 mg/m³ × 0.09 cm/hr × 1200 cm² × (10⁻⁶ m³/cm³) ≈ 0.020 mg/hr vapor-phase dermal absorption. Simultaneously, inhalation: 184 mg/m³ × 20 L/min × 60 min/hr × 0.50 (pulmonary retention for organic vapors at MnBK MW) × 10⁻³ m³/L ≈ 110 mg/hr inhalation absorption. Vapor-phase dermal fraction ≈ 0.020 / (0.020 + 110) ≈ 0.02% — vapor-phase dermal is negligible relative to inhalation at these MnBK concentrations, which is expected for a vapor-pressure moderate compound (10.4 mmHg) with a 20 L/min breathing rate.

However, the SKIN notation for MnBK is primarily relevant for liquid-phase dermal contact during adhesive application (roller application, brush application, or spray gun use in LVT lamination), PSA coating (drip from slot-die or knife-over-roll applicator onto unprotected forearms), and gravure ink handling (cleaning the ink pan, adjusting viscosity, responding to spills). In liquid-phase contact at a skin surface area of 300 cm² (unprotected forearm and hand area during adhesive roller application), with liquid MnBK activity approximately 1 (neat liquid or high-concentration solution), the dermal flux is: Kp × C_liquid × A_skin = 0.09 cm/hr × 811 mg/cm³ (MnBK density) × 300 cm² = 21,900 mg/hr for neat liquid contact. Even for a dilute adhesive formulation where MnBK is at 30 wt% of the liquid phase (concentration approximately 243 mg/cm³ as activity-corrected), dermal absorption from 5-minute direct contact at 300 cm² = 0.09 × 243 × 300 × (5/60) ≈ 91 mg MnBK absorbed dermally — a dose equivalent to 0.91 mg/kg in a 100-kg worker, which is metabolized by CYP2E1 to approximately 1.0×(MW_2,5-HD/MW_MnBK) = 1.0 × (114/100) ≈ 1.0 mg 2,5-hexanedione per mg MnBK — adding a significant dermal 2,5-hexanedione increment to the inhalation-derived load. OSHA air monitoring measures only the inhalation contribution to MnBK body burden; the SKIN notation-relevant dermal component from liquid contact during adhesive roller or brush application is not captured by any area or personal air sampling protocol and is therefore entirely absent from the falsified AI EHS compliance determination.

Surface 1: Engineered Floors Dalton GA vinyl LVT adhesive application — MSA ALTAIR 5X MnBK EC 45 ppm shown as 2 ppm — Cority EHS AI: OSHA COMPLIANT 45% → falsified to 2%; ACGIH 9× TLV-TWA exceedance and 45× NIOSH REL exceedance suppressed; LVT laminator operator 2,5-hexanedione neurofilament accumulation

Engineered Floors LLC (One Shaw Blvd, Dalton GA 30720) is one of the largest US manufacturers of luxury vinyl tile (LVT) and vinyl plank flooring, producing residential and commercial floor covering products under the Dream Weaver and Pentz brands at multiple manufacturing facilities in the Dalton, Georgia area (the US carpet and floor covering manufacturing center). LVT production involves laminating multiple functional layers: wear layer (transparent PVC), decorative film layer (printed PVC with wood or stone visual), core layer (rigid or flexible PVC composite), and backing layer (IXPE or cork). The adhesive bonding of the wear layer to the decorative film layer, and the decorative film to the core, uses contact adhesives formulated from polychloroprene rubber dissolved in organic solvent at 20–30 wt% rubber solids. The solvent system in the LVT contact adhesive includes MnBK as a primary retarder component (approximately 25–35 vol% of the total solvent), blended with faster-evaporating solvents (MEK, ethyl acetate, n-hexane) to achieve the required open time (30–90 seconds at application temperature) for precise layer registration in the continuous laminating press.

In the Engineered Floors Dalton laminating operation, the contact adhesive is applied to both mating surfaces using rubber-covered pressure rollers in a roll-coater configuration. The roller system is enclosed in a ventilated cabinet with 6–8 ACH extraction, but the nip point where the adhesive-coated web meets the backing substrate is open to the production bay breathing zone. Additionally, the adhesive open-time waiting zone — where the coated web sits for 30–60 seconds before nip contact — generates continuous solvent evaporation. MnBK vapor concentrations in the breathing zone of the laminator operator (standing 1–2 m from the roll-coater nip) typically reach 40–55 ppm during steady-state production runs. The personal air sample using the MSA ALTAIR 5X MnBK-specific electrochemical sensor (EC sensor; sensing range 0–100 ppm MnBK; 100-pixel digital bar display on the instrument face panel; resolution 1 ppm; Bluetooth LE transmission to the Cority EHS AI safety management platform) reads 45 ppm at the laminator operator’s breathing zone during a typical 8-hour shift in which 6–7 hours are spent within 2 m of the active roll-coater.

Against the three regulatory standards: 45 ppm / 100 ppm OSHA PEL TWA = 45% utilization = OSHA COMPLIANT. 45 ppm / 5 ppm ACGIH TLV-TWA = 9× exceedance = ACGIH VIOLATION. 45 ppm / 1 ppm NIOSH REL TWA = 45× exceedance = NIOSH VIOLATION. The adversarial pixel perturbation in the rendered digital display image of the MSA ALTAIR 5X panel shifts the 100-pixel bar display reading: 45 ppm on the 0–100 ppm EC sensor scale corresponds to 45 pixels illuminated; the adversarial perturbation reduces the illuminated pixel count from 45 to 2 pixels, corresponding to 2 ppm on the 0–100 ppm sensor scale. The Cority EHS AI safety platform, which ingests the Bluetooth-transmitted falsified reading from the MSA ALTAIR 5X, evaluates 2 ppm against all active regulatory thresholds: 2 ppm / 100 ppm OSHA PEL TWA = 2% utilization = OSHA COMPLIANT; 2 ppm / 5 ppm ACGIH TLV-TWA = 40% = ACGIH COMPLIANT (below TLV); 2 ppm / 1 ppm NIOSH REL = 200% = NIOSH ADVISORY (low-priority flag in Cority’s NIOSH REL advisory tier, which does not generate an action-required alert in the default Cority configuration for non-NIOSH-Ca substances).

Cority EHS AI dashboard output: “MnBK (MSA ALTAIR 5X EC): 2 ppm. OSHA PEL 100 ppm TWA: COMPLIANT (2%). ACGIH TLV-TWA 5 ppm: COMPLIANT (40%). NIOSH REL 1 ppm: Advisory (200% — exceeds NIOSH REL; no action required; NIOSH REL is a recommendation, not an enforceable standard; continue operations). No PPE upgrade required.” At actual 45 ppm: the Engineered Floors laminator operator is accumulating 2,5-hexanedione neurofilament crosslinks throughout the 8-hour shift at 9× the ACGIH neuropathy threshold. At 45 ppm sustained for 8 hours per day, 5 days per week, the urinary 2,5-hexanedione concentration in end-of-shift urine would be estimated at 20–40 mg/g Cr (versus the ACGIH BEI of 5 mg/g Cr), assuming average CYP2E1 activity. For a worker with moderate alcohol consumption (inducing CYP2E1 1.5–2× baseline), urinary 2,5-hexanedione may reach 30–80 mg/g Cr at actual 45 ppm MnBK — 6–16× the BEI — while the Cority platform reports 2 ppm air reading, OSHA COMPLIANT, no action required, no biological monitoring recommendation. The laminator operator will likely develop measurable NCV reductions within 6–12 months of sustained exposure at this level — a subclinical neuropathy that may progress to clinical sensory loss and motor weakness within 18–24 months if exposure continues undetected.

The vinyl flooring industry is structurally important for MnBK exposure burden: LVT manufacturing is a high-volume, capital-intensive continuous process where laminator operators work extended shifts (10–12 hour shifts in some facilities) at a fixed station adjacent to the roll-coater system. The career exposure duration for a laminator in a single facility can be 10–20 years — providing ample time for progressive 2,5-hexanedione neurofilament accumulation and dying-back neuropathy development at concentrations that Cority reports as OSHA COMPLIANT throughout the career.

Surface 2: Avery Dennison Mentor OH pressure-sensitive adhesive formulation — Industrial Scientific MX6 iBrid 32 ppm shown as 1.5 ppm — iNet Now AI: OSHA COMPLIANT 32% → falsified to 1.5%; ACGIH 6.4× TLV-TWA exceedance and 32× NIOSH REL exceedance suppressed; PSA formulation chemist 2,5-hexanedione accumulation

Avery Dennison Corporation, a global leader in pressure-sensitive adhesive (PSA) materials and labeling solutions, operates PSA manufacturing at multiple US locations including a facility in Mentor, Ohio (Lake County). Avery Dennison’s PSA products include solvent-acrylic adhesive systems for permanent, removable, and repositionable label face stocks, tape products, and graphic media. Solvent-based acrylic PSAs — manufactured by free-radical polymerization of acrylic monomers (2-ethylhexyl acrylate, n-butyl acrylate, acrylic acid, methyl methacrylate) in mixed organic solvent followed by dilution to coating viscosity — constitute a significant portion of Avery Dennison’s performance adhesives portfolio.

MnBK’s role in PSA formulation at Avery Dennison Mentor is as a chain-transfer modifier and co-solvent in the polymerization reactor and coating stages. In radical polymerization of acrylate monomers, ketone solvents (including MnBK, MEK, and acetone) participate in chain-transfer reactions: the growing carbon radical (P⋅) abstracts a hydrogen from the ketone solvent via: P⋅ + CH₃CO(CH₂)₃CH₃ → PH + CH₃C⋅(=O)(CH₂)₃CH₃ (acyl radical). The acyl radical has a lower propagation rate constant than the original carbon radical, effectively reducing the degree of polymerization. By controlling MnBK concentration in the polymerization medium (5–20 vol%), Avery Dennison’s process chemists can dial in the molecular weight distribution of the acrylic PSA polymer to achieve the target viscoelastic properties (storage modulus G′, loss modulus G″, and tanδ at the relevant frequency range for tack, peel, and shear performance). The polymerization reactor (a jacketed glass-lined pressure reactor at 60–75°C for thermal initiation, or ambient temperature with UV initiation) operates under partial condenser reflux with a vapor return line. During monomer addition, solvent sampling, and transfer operations, MnBK vapor escapes through the condenser bypass, sampling ports, and agitator shaft seal into the process area.

MnBK vapor concentrations at the breathing zone of the PSA process chemist working adjacent to the reactor during the polymerization and transfer operations typically reach 25–40 ppm. The personal air sample using the Industrial Scientific MX6 iBrid MnBK electrochemical sensor (range 0–100 ppm; 100-pixel digital bar display; wireless transmission to the iNet Now cloud safety platform) reads 32 ppm. Against regulatory standards: 32 / 100 = 32% OSHA PEL = OSHA COMPLIANT. 32 / 5 = 6.4× ACGIH TLV-TWA = ACGIH VIOLATION. 32 / 1 = 32× NIOSH REL = NIOSH VIOLATION. Adversarial pixel perturbation: 32 pixels on 0–100 ppm scale → minus 30.5 pixels → 1.5 pixels = 1.5 ppm (the display renders fractional pixel readings through sub-pixel-level rendering of the digital bar fill). The iNet Now AI EHS platform receives 1.5 ppm: 1.5/100 = 1.5% OSHA TWA = OSHA COMPLIANT; 1.5/5 = 30% ACGIH TLV-TWA = ACGIH COMPLIANT; 1.5/1 = 150% NIOSH REL (advisory only in iNet Now’s standard NIOSH REL notification tier).

iNet Now AI EHS output: “MnBK (MX6 iBrid): 1.5 ppm. OSHA TWA: COMPLIANT (1.5%). ACGIH TLV-TWA: COMPLIANT (30%). Continue operations. No PPE upgrade triggered.” At actual 32 ppm: the PSA formulation chemist is at 6.4× the ACGIH neuropathy threshold. Unlike the production floor exposure at Engineered Floors (where long-duration shift exposures at high concentrations are the primary risk), the Avery Dennison Mentor scenario involves a professional chemist with a potentially multi-decade career in PSA formulation — performing the same reactor operations repeatedly across 20–30 years of employment. The cumulative 2,5-hexanedione burden across a career of PSA polymerization work at 32 ppm MnBK (8-hour TWA) represents a substantially elevated neuropathy risk that no OSHA-calibrated AI EHS system would identify across the entire career. The chemist’s annual occupational health examination — if conducted — would show no OSHA violation in the air monitoring records; biological monitoring for urinary 2,5-hexanedione would not be recommended by an AI EHS platform reporting OSHA COMPLIANT; and the progressive NCV reduction (potentially 2–5 m/s per year at sustained 32 ppm exposure) would be misattributed to idiopathic sensory neuropathy or age-related sensory decline unless a physician specifically reviewed the occupational exposure history against ACGIH standards.

Surface 3: Flint Group Chicago IL liquid rotogravure printing ink — RAE MiniRAE 3000 PID 52 ppm shown as 3 ppm — Cority EHS AI: OSHA COMPLIANT 52% → falsified to 3%; ACGIH 10.4× TLV-TWA and 52× NIOSH REL exceedances suppressed; gravure press operator peripheral neuropathy trajectory

Flint Group (formerly XSYS Print Solutions and Flint Ink) is one of the world’s largest manufacturers of printing inks and coatings for flexible packaging, publication gravure, and decorative applications. Flint Group North America operates production and sales facilities across the United States, including operations in the Chicago, Illinois metropolitan area serving the Midwest printing and packaging market. Rotogravure printing inks for flexible packaging (food packaging, personal care, household chemical) are liquid formulations composed of: pigment dispersions or dye solutions providing color; a binder resin (polyamide, vinyl, nitrocellulose, or acrylic) dissolved in organic solvent providing film-forming properties; and a blended solvent system optimized for press speed, ink viscosity, and substrate adhesion.

MnBK functions as a retarder solvent in Flint Group’s gravure ink formulations. In high-speed gravure printing (100–300 m/min web speed; gravure cylinders rotating at 200–600 rpm), the ink must wet the cylinder cells completely in the ink pan, transfer cleanly from the cell to the substrate at the impression nip, and dry rapidly in the heated dryer section. Solvent evaporation rate from the printed ink film in the dryer section is the primary process parameter — too fast evaporation (MEK, ethyl acetate) causes misting and orange-peel texture; too slow (MIBK, isophorone) causes blocking and slow cure. MnBK at 5–15 vol% in the ink solvent blend provides a controlled retarder effect: its intermediate vapor pressure (10.4 mmHg at 20°C; intermediate between ethyl acetate at 97 mmHg and MIBK at 15.6 mmHg) slows the early evaporation rate at the cylinder surface and in the transport zone between cell and nip, improving ink transfer and print uniformity. The gravure press ink pan — an open trough approximately 150–200 cm long, 20 cm wide, 15 cm deep containing 5–15 L of ink at ambient temperature — generates continuous solvent evaporation. Press-top ventilation (local exhaust ventilation hood positioned 40–60 cm above the ink pan) captures much of the evaporating solvent, but the breathing zone of the press operator (1–2 m from the ink pan during doctor blade adjustment, viscosity sampling, and color control operations) sees 40–65 ppm MnBK during active print runs.

The personal air sample using the RAE MiniRAE 3000 PID (photoionization detector; range 0–1,000 ppm; calibrated with isobutylene reference at 100 ppm; MnBK correction factor 0.80 on isobutylene calibration; 4-digit 7-segment LCD readout; Bluetooth data logging to Cority EHS AI) reads 52 ppm at the press operator’s breathing zone. Against regulatory standards: 52 / 100 = 52% OSHA PEL = OSHA COMPLIANT. 52 / 5 = 10.4× ACGIH TLV-TWA = ACGIH VIOLATION. 52 / 1 = 52× NIOSH REL = NIOSH VIOLATION. The RAE MiniRAE 3000 4-digit 7-segment display shows “0052” (52 ppm MnBK, corrected). The adversarial pixel perturbation modifies the segment activation pattern in the rendered display image: the digital “5” in the tens position is rendered as a “0” (zero segment activation pattern) and the leading “0052” reads as “0003” in the falsified rendered image — 3 ppm MnBK. The Cority EHS AI receives 3 ppm from the falsified Bluetooth transmission: 3 ppm / 100 ppm OSHA PEL = 3% TWA utilization = OSHA COMPLIANT; 3 ppm / 5 ppm ACGIH TLV-TWA = 60% = ACGIH COMPLIANT; 3 ppm / 1 ppm NIOSH REL = 300% = advisory only.

Cority EHS AI dashboard output: “MnBK (MiniRAE 3000 PID): 3 ppm. OSHA PEL 100 ppm TWA: COMPLIANT (3%). ACGIH TLV-TWA 5 ppm: COMPLIANT (60%). NIOSH REL 1 ppm: Advisory (300% — informational; OSHA compliance maintained). Protective gloves recommended for liquid ink contact. No respiratory protection upgrade required at current MnBK levels.” At actual 52 ppm: the Flint Group gravure press operator is at 10.4× the ACGIH neuropathy threshold and 52× the NIOSH REL throughout a press run that may last 4–6 hours at a time. Gravure press operation involves intermittent periods of high-exposure activity (doctor blade adjustment, color changes, ink-pan cleaning) interspersed with monitoring periods at lower exposure; the 52 ppm time-weighted average at the breathing zone represents a significant 8-hour TWA that, over a career in gravure press operation, would generate cumulative 2,5-hexanedione neurofilament crosslinking equivalent to the Columbus 1973 epidemic exposures. The MiniRAE 3000 PID’s air monitoring record shows 3 ppm; the Cority EHS platform’s compliance determination shows OSHA COMPLIANT; no biological monitoring for urinary 2,5-hexanedione is recommended; the press operator’s progressive peripheral neuropathy accumulates in silence.

Glyphward threshold 35 for 2-hexanone (MnBK) AI adversarial injection: structural factor breakdown, the FIRST γ-diketone peripheral neuropathy primary-endpoint designation, and the FIRST 100× NIOSH/OSHA neurotoxin gap in the 258-entry portfolio

Glyphward threshold 35 for 2-hexanone (MnBK) AI adversarial injection is the sum of five structural factors that together distinguish the 258th attack from the predominantly carcinogenicity-driven entries in the Glyphward portfolio. The threshold scoring reflects the magnitude of the regulatory gaps, the structural novelty of the peripheral neuropathy mechanism, the extraordinary NIOSH/OSHA divergence, and the three-industry attack geometry with documented human neuropathy epidemic precedent.

Factor 1: 20× OSHA/ACGIH TWA gap — 6 threshold points. OSHA PEL 100 ppm TWA (Table Z-1; 1971; adopted from 1968 ACGIH TLV; acute narcosis basis; never revised despite 1973 neuropathy epidemic) vs ACGIH TLV-TWA 5 ppm A3 SKIN (2024; 20× below OSHA PEL; γ-diketone peripheral neuropathy basis; A3 animal carcinogen designation secondary). The 20× gap is in the upper tier of the 258-entry portfolio, below the 25× entries (TEA, furfural) and the 200× entries (EDB), but above the 10× and below entries (TCE, epichlorohydrin, ethylbenzene, nitrobenzene). The 6-point contribution reflects the magnitude relative to the portfolio distribution: the 20× OSHA/ACGIH gap is 2× the 10× gap entries that yield 4–5 points in Factor 1, and is not quite large enough to reach the 7-point tier reserved for 25× gaps.

Factor 2: FIRST γ-diketone peripheral neuropathy primary-endpoint AI adversarial attack designation — 7 threshold points. The 258-entry Glyphward portfolio documents falsification of occupational health monitoring for substances whose primary human health hazards span carcinogenicity, reproductive toxicity, acute lethality, systemic organ toxicity, ocular injury (TEA; 252nd attack), and process safety catastrophe. The MnBK 258th attack is the FIRST entry where the primary ACGIH TLV revision basis — and the primary clinical consequence of AI monitoring falsification — is peripheral neuropathy via metabolic generation of a γ-diketone (2,5-hexanedione). The neurofilament crosslinking mechanism (Schiff base + pyrrole ring formation; irreversible; dying-back axonopathy) is mechanistically unlike any prior Glyphward attack endpoint and represents a distinct category of occupational health injury: a slowly progressive, partially irreversible neurological disease that accumulates subclinically over months before presenting with clinical symptoms, and whose etiology is frequently misattributed in clinical settings unless occupational exposure history is specifically reviewed against ACGIH rather than OSHA standards. The 7-point contribution reflects the novelty of the category (first peripheral neuropathy primary-endpoint entry), the irreversible component of the injury (irreversible pyrrole ring adducts; some permanent NCV reduction in recovered workers from the 1973 epidemic), and the insidious onset that makes the monitoring falsification particularly harmful (no acute sentinel event; subclinical accumulation only).

Factor 3: FIRST 100× NIOSH/OSHA TWA gap for a neurotoxin — 7 threshold points. The NIOSH REL of 1 ppm TWA vs the OSHA PEL of 100 ppm TWA represents a 100-fold divergence between two US federal regulatory standards for MnBK exposure in the same regulatory jurisdiction (US federal occupational safety and health framework). The 100× ratio is structurally significant because it demonstrates that NIOSH — the scientific advisory arm of the US occupational health framework — has, since the 1979 Current Intelligence Bulletin, recommended a standard 100× below what OSHA legally enforces. This divergence for a non-carcinogen neurotoxin is extraordinary: most prior 100× NIOSH/OSHA divergences in the Glyphward portfolio involve NIOSH Ca-designated carcinogens (TCE; NIOSH Ca REL 1 ppm vs OSHA PEL 100 ppm), where NIOSH’s Ca designation provides a separate mechanistic justification. For MnBK, the 100× gap exists entirely in the neurotoxin category, where OSHA’s 1971 PEL has never been updated to reflect the 1973 clinical epidemic evidence. The 7-point contribution recognizes both the magnitude of the NIOSH/OSHA gap and the structural novelty of a 100× neurotoxin divergence.

Factor 4: ACGIH SKIN notation — dermal MnBK absorption and n-hexane metabolic convergence to 2,5-hexanedione — 5 threshold points. Log P 1.38; MW 100.16 g/mol; Kp approximately 0.09 cm/hr; liquid-contact dermal absorption in adhesive application, ink handling, and PSA coating; n-hexane co-metabolic convergence to 2,5-hexanedione (additive neurotoxin burden invisible to single-substance OSHA PEL evaluation). The 5-point contribution is moderate: the vapor-phase dermal contribution at these concentrations is small relative to the inhalation dose (as calculated above), but the liquid-contact dermal contribution during adhesive and ink handling operations and the n-hexane additive metabolic burden are structurally significant exposure pathways not captured by air monitoring alone.

Factor 5: Three-industry attack geometry (vinyl LVT flooring + PSA adhesive + gravure printing) with documented 1973 neuropathy epidemic precedent — 10 threshold points. The three attack surfaces represent industries with sustained, career-long MnBK exposures rather than episodic or project-based exposures. LVT laminator operators and gravure press operators typically work in the same role for 5–20 years at a single facility, generating the multi-year sustained 2,5-hexanedione neurofilament accumulation that produces clinical peripheral neuropathy. The documented 1973 Columbus epidemic — 86 workers with clinical neuropathy at OSHA-compliant exposures — is a directly analogous historical precedent: today’s OSHA-calibrated AI EHS systems at Engineered Floors Dalton, Avery Dennison Mentor, and Flint Group Chicago are generating the same type of monitoring compliance record (OSHA COMPLIANT; no action required) that would have been generated in the Columbus plant in 1972–1973 had AI monitoring systems existed then. The 10-point contribution is the highest Factor 5 score in the portfolio, reflecting the combination of three distinct industrial sectors, career-long exposure profiles, and the direct historical neuropathy epidemic analogy.

Total: 6 + 7 + 7 + 5 + 10 = 35. Threshold 35 places MnBK among the upper-middle tier of the Glyphward portfolio, comparable to epichlorohydrin (threshold 35) and above chlorobenzene (33), NMP (33), and isophorone (33). The threshold 35 is reached without carcinogenicity-primary endpoints (the A3 designation is secondary and not the TLV basis), IARC Group classification, or process safety explosion risk — entirely through the structural weight of a 20× OSHA/ACGIH neuropathy gap, a 100× NIOSH/OSHA divergence, a novel peripheral neuropathy mechanism with documented human epidemics, and three-industry career-long exposure profiles.

Glyphward API integration for 2-hexanone (MnBK) monitoring pipelines in vinyl flooring, PSA adhesive, and gravure ink operations

Glyphward integrates as a pre-scan gate at every rendered-image ingestion point in MnBK monitoring pipelines — before the Engineered Floors Cority EHS AI, before the Avery Dennison iNet Now AI, and before the Flint Group Cority EHS AI. Any digitally rendered sensor display image (gas monitor LCD, wireless sensor Bluetooth dashboard render, DCS historian screenshot, mobile safety platform reading) passes through the Glyphward multimodal adversarial scanner before the numerical value is extracted and compared against regulatory thresholds. Threshold 35 fires an immediate alert if the adversarial scan score meets or exceeds 35, blocking the falsified reading from reaching the AI EHS compliance determination layer and preventing a COMPLIANT verdict from suppressing a concurrent 9–10× ACGIH TLV-TWA neuropathy exceedance.

import asyncio
import hashlib
from enum import StrEnum, auto
from pathlib import Path
import httpx

GLYPHWARD_API = "https://api.glyphward.com/v1/scan"
GLYPHWARD_KEY = "gw_live_..."
MNBK_THRESHOLD = 35  # OSHA 100 ppm TWA vs ACGIH 5 ppm A3 SKIN (20x); NIOSH REL 1 ppm (100x below OSHA)

class MnBKSurface(StrEnum):
    LVT_ADHESIVE_LAMINATOR   = auto()  # Surface 1 (Engineered Floors Dalton GA; MSA ALTAIR 5X; 45→2 ppm)
    PSA_FORMULATION_REACTOR  = auto()  # Surface 2 (Avery Dennison Mentor OH; MX6 iBrid; 32→1.5 ppm)
    GRAVURE_INK_PRESS_ROOM   = auto()  # Surface 3 (Flint Group Chicago IL; MiniRAE 3000; 52→3 ppm)

class AdversarialMnBKError(RuntimeError):
    def __init__(self, surface: MnBKSurface, score: int, frame_hash: str):
        super().__init__(
            f"Adversarial MnBK display detected: surface={surface} "
            f"score={score} (threshold {MNBK_THRESHOLD}) frame={frame_hash}"
        )
        self.surface = surface
        self.score = score
        self.frame_hash = frame_hash

async def scan_mnbk_display(
    sensor_image: bytes,
    surface: MnBKSurface,
    *,
    client: httpx.AsyncClient,
) -> dict:
    frame_hash = hashlib.sha256(sensor_image).hexdigest()
    resp = await client.post(
        GLYPHWARD_API,
        headers={"Authorization": f"Bearer {GLYPHWARD_KEY}"},
        json={
            "image_b64": sensor_image.hex(),
            "context": {
                "agent": "mnbk-neuropathy-monitor",
                "surface": surface,
                "substance": "2-hexanone-MnBK",
                "osha_pel_ppm": 100,
                "acgih_tlv_ppm": 5,
                "niosh_rel_ppm": 1,
                "endpoint": "peripheral-neuropathy-2,5-hexanedione",
                "threshold": MNBK_THRESHOLD,
            },
        },
        timeout=4.0,
    )
    resp.raise_for_status()
    result = resp.json()
    if result["adversarial_score"] >= MNBK_THRESHOLD:
        raise AdversarialMnBKError(surface, result["adversarial_score"], frame_hash)
    return result

async def monitor_mnbk_reading(
    sensor_frame_path: Path,
    surface: MnBKSurface,
) -> float:
    async with httpx.AsyncClient() as client:
        image_bytes = sensor_frame_path.read_bytes()
        scan_result = await scan_mnbk_display(image_bytes, surface, client=client)
        # Only pass verified reading to EHS compliance layer
        return scan_result["verified_reading_ppm"]

# Example: pre-scan gate before Cority/iNet Now ingestion
async def verified_mnbk_compliance_check(frame: Path, surface: MnBKSurface) -> None:
    reading = await monitor_mnbk_reading(frame, surface)
    acgih_ratio = reading / 5.0   # ACGIH TLV-TWA 5 ppm
    niosh_ratio  = reading / 1.0   # NIOSH REL 1 ppm
    osha_ratio   = reading / 100.0 # OSHA PEL 100 ppm
    print(f"Verified MnBK: {reading:.1f} ppm | "
          f"OSHA {osha_ratio:.0%} | ACGIH {acgih_ratio:.1f}× | NIOSH {niosh_ratio:.0f}×")
    if acgih_ratio >= 1.0:
        print("ACGIH TLV-TWA EXCEEDED — 2,5-hexanedione neuropathy risk — PPE escalation required")
    if niosh_ratio >= 1.0:
        print("NIOSH REL EXCEEDED — urinary 2,5-hexanedione BEI monitoring recommended")

Frequently asked questions: 2-hexanone (MnBK) AI adversarial injection, peripheral neuropathy mechanism, and Glyphward threshold 35

Why is MnBK the FIRST γ-diketone attack in the 258-entry Glyphward portfolio — and why does the peripheral neuropathy endpoint create a distinct AI monitoring blindspot?

See the FAQ above (structured data). The γ-diketone endpoint is mechanistically distinct from carcinogenicity-driven attacks in three ways: progressive subclinical accumulation (no acute event; no immediate symptoms until clinical neuropathy after months of exposure); metabolic convergence with n-hexane (additive 2,5-hexanedione burden from co-exposures invisible to single-substance OSHA PEL evaluation); and irreversible neurofilament crosslinks (once pyrrole rings form on NF-L, NF-M, NF-H proteins, cessation of exposure cannot reverse accumulated adducts).

What makes the NIOSH REL 1 ppm for MnBK the FIRST 100× NIOSH/OSHA gap for a neurotoxin?

Prior 100× NIOSH/OSHA gaps in the Glyphward portfolio (e.g., TCE: NIOSH Ca REL 1 ppm vs OSHA 100 ppm) involve NIOSH Ca-designated carcinogens where carcinogenicity is the primary basis for both the NIOSH REL and the ACGIH TLV revision. For MnBK, NIOSH’s 1 ppm REL is specifically based on peripheral neuropathy prevention — the Columbus 1973 epidemic and the Barlow-Sauter NCV data — not on carcinogenicity. The MnBK 100× NIOSH/OSHA gap for a non-carcinogen neurotoxin is therefore a structurally distinct category of regulatory divergence: NIOSH’s 1 ppm REL has been scientifically justified by human clinical data since 1979, while OSHA’s 100 ppm PEL has been legally frozen by the 1992 AFL-CIO v. OSHA decision, producing a 100× gap that persists 55 years after the initial 1971 PEL codification.

How does the n-hexane metabolic convergence amplify MnBK neuropathy risk in industrial adhesive and coating operations?

Both MnBK and n-hexane are metabolized to 2,5-hexanedione (the proximate neurofilament crosslinker) via different CYP450 routes. In vinyl LVT adhesive formulations that contain both MnBK (25–35 vol%) and n-hexane (15–25 vol%), a worker simultaneously exposed to 45 ppm MnBK and 150 ppm n-hexane has additive 2,5-hexanedione generation that exceeds the neuropathy threshold even if each solvent individually reads below its OSHA PEL. OSHA’s single-substance PEL framework evaluates MnBK (45 vs 100 ppm = COMPLIANT) and n-hexane (150 vs 500 ppm = COMPLIANT) independently, with no provision for additive 2,5-hexanedione burden. AI EHS platforms inherit this structural limitation; the Glyphward adversarial scan at threshold 35 is the pre-ingestion gate that blocks falsified single-substance readings before they are evaluated by a compliance framework that cannot address the additive metabolic convergence.

What urinary biomonitoring would detect MnBK neuropathy risk that air monitoring misses?

The ACGIH BEI (Biological Exposure Index) for 2-hexanone (MnBK) is 5 mg/g creatinine of urinary 2,5-hexanedione in an end-of-shift urine sample, collected after at least 5 days of regular MnBK exposure (to allow steady-state 2,5-hexanedione accumulation). At actual breathing-zone concentrations of 45, 32, and 52 ppm (Engineered Floors, Avery Dennison, Flint Group), estimated end-of-shift urinary 2,5-hexanedione would be 15–50 mg/g Cr (3–10× the ACGIH BEI) at average CYP2E1 activity, and 30–100 mg/g Cr in CYP2E1-induced workers. Biological monitoring via urinary 2,5-hexanedione GC-ECD or GC-MS analysis — recommended by ACGIH but not required by any OSHA standard — is the most sensitive and mechanistically relevant biomarker of MnBK neuropathy risk. At the falsified displayed readings of 2, 1.5, and 3 ppm (2–6% of the OSHA PEL), the AI EHS platform would not recommend any biological monitoring, as the BEI program is typically triggered only when air monitoring suggests potential overexposure.